García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, Reyes-Cabello E, González-González JA, Muñoz-Espinosa LE, Vázquez-Elizondo G, Villarreal-Pérez JZ, Maldonado-Garza HJ

Idioma: Ingles.
Referencias bibliográficas: 41
Paginas: 240-248
Archivo PDF: 159.24 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007; 120: 829-34.

2. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: A review and update. Dig Dis Sci 2010; 55: 560-78.

3. Blendea MC, Thompson MJ, Malkani S. Diabetes and chronic liver disease: Etiology and pitfalls in monitoring. Clin Diabetes 2010; 28: 139-44.

4. Porepa L, Ray JG, Sanchez-Romeu P, Booth GL. Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 2010; 182: 526-31.

5. García-Compean D, Jaquez-Quintana JO, Maldonado-Garza H. Hepatogenous diabetes: current views of an ancient problem. Ann Hepatol 2009: 8: 13-20.

6. Holstein A, Hinze S, Thiessen E, Plaschke A, Egberts EH. Clinical implications of hepatogenous diabetes in liver cirrhosis. J Gastroenterol Hepatol 2002; 17: 677-81.

7. Nishida T, Tsuji S, Tsujii M, Arimitsu S, Haruna Y, Imano E, Suzuki M, et al. Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis. Am J Gastroenterol 2006; 101: 70-5.

8. Del Vecchio-Blanco C, Gentile S, Marmo R, Carbone L, Coltorti M. Alterations of glucose metabolism in chronic liver disease. Diabetes Res Clin Pract 1990; 8: 29-36.

9. Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-43.

10. Picardi A, D’Avola D, Gentilucci UV, Galati G, Fiori E, Spataro S, Afeltra A. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab Res Rev 2006; 22: 274-83.

11. Nielsen MF, Caumo A, Aagaard NK, Chandramouli V, Schumann WC, Landau BR, Schmitz O, et al. Contribution of defects in glucose uptake to carbohydrate intolerance in liver cirrhosis: assessment during physiological glucose and insulin concentrations. Am J Physiol Gastrointest Liver Physiol 2005; 288: 1135-43.

12. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab Care 2011; 34(Suppl. 1): S62-S69.

13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.

14. Cortez-Pinto H, Carneiro de Moura M, Paul Day C. Non-alcoholic steatohepatitis: From cell biology to clinical practice. J Hepatol 2006; 44: 197-208.

15. Raddatz D, Ramadori G. Carbohydrate metabolism and the liver: actual aspects from physiology and disease. Z Gastroenterol 2007; 45: 51-62.

16. Bianchi G, Marchesini G, Zoli M, Bugianesi E, Fabbri A, Pisi E. Prognostic significance of diabetes in patients with cirrhosis. Hepatology 1994; 20: 119-25.

17. Jáquez-Quintana JO, García-Compean, González-González JA, Villarreal-Pérez JZ, Lavalle-González FJ, Muñoz- Espinosa LE, López-Hernández PL, et al. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Ann Hepatol 2011; 10: 56-62.

18. Nguyen DM, El-SeragHB. The epidemiology of obesity. Gastroenterol Clin North Am 2010; 39: 1-7.

19. Barquera S, Campos-Nonato I, Hernández-Barrera L, Flores M, Durazo-Arvizu R, Kanter R, Rivera JA. Obesidad y adiposidad central en adultos mexicanos: resultados de la Encuesta Nacional de Salud y Nutrición 2006. Sal Pub Mex 2009; 51(Suppl. 4): S595-S603.

20. Tellez FI, Sanchez F, Garcia M, Chavez Tapia N, Franco AM, Lopez G, Cerda E, et al. Prevalence of metabolic síndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008; 14: 4771-5.

21. Macías-Rodríguez RU, Torre A. Pathophysiology of non-alcoholic steatohepatitis. An insulin resistance overview. Rev Invest Clin 2009; 61: 4771-5.

22. Romero-Gomez M, Viloria MM, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Copras R, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636.

23. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.

24. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.

25. Patrick S, Kamath W, Ray Kim. The Model for End-Stage Liver Disease (MELD). Hepatology 2007; 45: 797-805.

26. Kobashi-Margáin RA, Gutiérrez-Grobe Y, Ponciano-Rodríguez G, Uribe M, Méndez-Sánchez N. Prevalence of type 2 diabetes mellitus and chronic liver disease: a retrospective study of the association of two increasingly common diseases in Mexico. Ann Hepatol 2010; 9: 282-8.

27. Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 21; 15: 280-8.

28. Cortez-Pinto H, Carneiro de Moura M, Paul Day C. Comparison of surrogate and direct measurement of insulin resistance in chronic hepatitis C virus infection: impact of obesity and ethnicity. Hepatology 2010; 52: 38-46.

29. Wree A, Kahraman A, Gerken G, Canbav A. Obesity affects the liver-the link between adipocytes and hepatocytes. Digestion 2011; 83: 124-33.

30. Goral V, Atalay R, Kucukoren M. Insulin resistance in liver cirrhosis. Hepatogastroenterology 2010; 57: 309-15.

31. Molitch ME, De Fronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, Steffes MW. American Diabetes Association. Nephropathy in diabetes. Diab Care 2004; 27(Suppl.1): S79-S83.

32. Martín-Llahí M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R, Solá E, et al. Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology 2011; 140: 488-96.

33. Marchesini G, Ronchi M, Forlani G, Bugianesi E, Bianchi G, Fabbri A, Zoli M, et al. Cardiovascular disease in cirrhosisa point-prevalence study in relation to glucose tolerance. Am J Gastroenterol 1999; 94: 655-62.

34. Roden M. Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2006; 2: 335-48.

35. Whitehead JP, Richards AA, Hickman IJ, Macdonald GA, Prins JB. Adiponectin-a key adipokine in the metabolic syndrome. Diab Obes Metab 2006; 8: 264-80.

36. Bertolani C, Marra F. The role of adipokines in liver fibrosis. Pathophysiology 2008; 15: 91-101.

37. Jonsson JR, Moschen AR, Hickman IJ, Richardson MM, Kaser S, Clouston AD, Powell EE, et al. Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol 2005; 43: 929-36.

38. Svegliati-Baroni G, Ridolfi F, Di Sario A, Casini A, Marucci L, Gaggiotti G, Orlandoni P, et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 1743-51.

39. Tietge UJ, Böker KH, Manns MP, Bahr MJ l. Elevated circulating adiponectin levels in liver cirrhosis are associated with reduced liver function and altered hepatic hemodynamics. Am J Physiol Endocrinol Metab 2004; 287: 82-9.

40. Sorrentino P, Tarantino G, Conca P, Perrella A, Perella O. Clinical presentation and prevalence of spontaneous bacterial peritonitis in patients with cryptogenic cirrhosis and features of metabolic syndrome. Can J Gastroenterol 2004; 18: 381-6.

41. Cheruvattath R, Balan V. Infections in patients with end-stage liver disease. J Clin Gastroenterol 2007; 41: 403-11.